High Bioavailability Resveratrol Delivery System: A Novel Nutritional Strategy for the Prevention and Alleviation of Rheumatoid Arthritis

This study aimed to develop an oral solid dispersion nutrient delivery system of resveratrol (RSV) and Eudragit E PO (E PO) for the prevention of rheumatoid arthritis. The RSV-E PO solid dispersion, prepared by the solvent method at a drug-polymer ratio of 1:7 (w/w), turned resveratrol into an amorphous state, as proved by SEM, DSC, XRD, and FTIR. Over 80% of resveratrol was released in vitro, a 13-fold increase compared to raw resveratrol. In male Sprague-Dawley rats, its oral administration (20 mg·kg^-1) doubled bioavailability versus unformulated resveratrol. Evaluated in an adjuvant-induced arthritis (AIA) model, the compound demonstrated significant anti-arthritic effects. These protective effects were primarily mediated through the modulation of key inflammatory and oxidative stress pathways, as evidenced by a marked reduction in pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and malondialdehyde (MDA) levels, coupled with an increase in the anti-inflammatory cytokine IL-10 and the antioxidant enzyme superoxide dismutase (SOD). Also, its safety was confirmed by stable AST, ALT, CREA, and BUN levels. In summary, the RSV-E PO solid dispersion, with better dissolution and bioavailability, serves as an effective oral nutrient delivery system for RSV.